Mutational load of the mitochondrial genome predicts pathological features and biochemical recurrence in prostate cancer.

ABSTRACT: Prostate cancer management is complicated by extreme disease heterogeneity, which is further limited by availability of prognostic biomarkers. Recognition of prostate cancer as a genetic disease has prompted a focus on the nuclear genome for biomarker discovery, with little attention given to the mitochondrial genome. While it is evident that mitochondrial DNA (mtDNA) mutations are acquired during prostate tumorigenesis, no study has evaluated the prognostic value of mtDNA variation. Here we used next-generation sequencing to interrogate the mitochondrial genomes from prostate tissue biopsies and matched blood of 115 men having undergone a radical prostatectomy for which there was a mean of 107 months clinical follow-up. We identified 74 unique prostate cancer specific somatic mtDNA varian

SUBMITTER: Kalsbeek AM 

PROVIDER: S-EPMC5191864 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature